5 results about "Chorioallantoic membrane" patented technology

The invention discloses a combined evaluation method for in-vitro and in-vivo red fading and relieving effects of cosmetic raw materials, which comprises the following steps: in-vitro model evaluation: inducing a human immortalized umbilical vein endothelial cell model by adopting TNF-alpha, and detecting the secretion amount of a prostacyclin I2 factor to obtain a score of an in-vitro model; in-vivo model evaluation: adopting a chick embryo chorioallantoic membrane model, and obtaining a score of the in-vivo model according to the degree of vasoconstriction caused by the to-be-detected raw material sample acting on the chick embryo chorioallantoic membrane; and comprehensive evaluation: based on the score of the in-vitro model and the score of the in-vivo model, comprehensively evaluating the red fading and relieving efficacy of the raw material sample to be tested. According to the technical scheme, the defect that in the prior art, no cosmetic raw material soothing efficacy evaluation method for the vascular reactivity increasing mechanism exists is overcome, efficacy evaluation is more accurate, the method has the advantages of being comprehensive, short in test period, easy to operate, economical and convenient, and an effective reference basis is provided for screening and compounding schemes of red fading and soothing raw materials.

The invention provides a method for evaluating eye irritation of cosmetics, and relates to the technical field of detection. The method comprises the following steps: firstly, acquiring a first image of a chick embryo chorioallantoic membrane before contacting a to-be-detected sample; removing the to-be-detected sample contact film after a preset time to obtain a second image; performing color channel separation on the two images, and selecting a green channel image to perform gray value analysis to obtain a first gray value and a second gray value; and finally evaluating the eye irritation level of the sample to be detected according to the gray value difference. According to the method disclosed by the invention, quantitative evaluation on eye irritation is realized by utilizing the optical characteristic of chick embryo blood vessels to green light, the subjective defect that a traditional chick embryo chorioallantoic membrane test depends on visual inspection is overcome, the objectivity, accuracy and repeatability of a detection result are remarkably improved, the operation is simple and convenient, and animal ethical dispute is avoided.

The invention discloses eye drops for treating vascular hyperplasia of eyes and a preparation method of the eye drops, and belongs to the technical field of biological pharmacy. The eye drops comprise a recombinant human angiostatin protein, an endostatin protein and a pharmaceutically acceptable carrier, wherein the recombinant human angiostatin protein and the endostatin protein are used for preparing the eye drops. Experiments show that the eye drops show remarkable vascular inhibition activity in a chick embryo chorioallantoic membrane model and a diabetic rat retina hyperplasia model, and the two proteins are combined for use to achieve a synergistic effect; the invention provides a safe and effective new way for local treatment of ocular vascular hyperplasia diseases.

The invention provides a bovine nodular dermatosis virus passage attenuating method and application thereof.The method comprises the steps that a bovine nodular dermatosis virus LSDV NM2020 strain serves as a parent strain, 25 generations of continuous passage is conducted through 9-day-old SPF chick embryo chorioallantoic membrane, 30 generations of continuous passage is conducted in Vero E6 cells in a gradual cooling mode, and finally the attenuated strain is obtained through plaque cloning and purification; the strain is named as an LSDV-Z strain. The low virulent strain shows good safety in cattle while keeping the growth titer close to that of a parent strain, does not cause clinical symptoms and does not have an external detoxification phenomenon. A virus attack protection test proves that the LSDV-Z strain can provide 100% immune protection for virulent virus attack. The method disclosed by the invention has the advantages of short attenuation period, high efficiency, no need of transgenic operation and the like, and the obtained LSDV-Z strain can be used as a safe and effective candidate vaccine strain and is used for preventing and controlling bovine nodular dermatosis.

The application discloses a combined evaluation method for the in-vitro and in-vivo redness-reducing soothing effect of a cosmetic raw material, which comprises in-vitro model evaluation, adoption of a human immortalized umbilical vein endothelial cell model induced by TNF-alpha, acquisition of the in-vitro model score by detecting the secretion amount of prostacyclin I2 factor, in-vivo model evaluation, adoption of a chicken embryo chorioallantoic membrane model, acquisition of the in-vivo model score by the degree of blood vessel contraction caused by the action of the sample to be tested on the chicken embryo chorioallantoic membrane, and comprehensive evaluation of the redness-reducing soothing effect of the sample to be tested based on the in-vitro model score and the in-vivo model score. The technical scheme of the application makes up for the defect of the prior art that there is no cosmetic raw material soothing effect evaluation method for the mechanism of increased vascular reactivity, the effect evaluation is more accurate, and the method has the advantages of comprehensiveness, short test cycle, simple operation, economy and convenience, and provides an effective reference for the screening and compounding scheme of redness-reducing soothing raw materials.